Breadcrumb
  1. Home
  2. 340B Drug Pricing Program
  3. Program Integrity
  4. FY 2017 Manufacturer Audit Results

FY 2017 Manufacturer Audit Results

Updated 9/11/18. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.

Results posted for 5 audits.
Manufacturer Labeler Codes Reviewed State OPA Findings Sanction Sort descending Corrective Action Status
Biogen U.S. Corp. 59627
64406
MA

No adverse findings

None

N/A

Shire US, Inc. 42227
47783
59417
54092
58521
66593
68875
64193
00944
PA

No adverse findings

None

N/A

EMD Serono, Inc. 44087 MA

No adverse findings

None

N/A

Jacksonville Pharmaceuticals, Inc. 70003 FL

No adverse findings

None

N/A

Pharmacyclics, LLC 57962 CA

No adverse findings

None

N/A

Date Last Reviewed: